Loading...
XETRBAYN
Market cap19bUSD
Dec 20, Last price  
18.94EUR
1D
0.37%
1Q
-33.91%
Jan 2017
-80.52%
Name

Bayer AG

Chart & Performance

D1W1MN
XETR:BAYN chart
P/E
—
P/S
0.39
EPS
—
Div Yield, %
12.67%
Shrs. gr., 5y
0.87%
Rev. gr., 5y
3.77%
Revenues
47.64b
-6.11%
29,735,880,80027,362,398,48028,955,881,04032,385,000,00032,918,000,00031,168,000,00035,088,000,00036,528,000,00039,760,000,00040,157,000,00042,239,000,00046,324,000,00046,769,000,00035,015,000,00039,586,000,00043,545,000,00041,400,000,00044,081,000,00050,739,000,00047,637,000,000
Net income
-2.94b
L
602,684,5601,594,057,2801,694,952,5304,711,000,0001,719,000,0001,359,000,0001,301,000,0002,470,000,0002,446,000,0003,189,000,0003,426,000,0004,110,000,0004,531,000,0007,336,000,0001,695,000,0002,430,000,000-15,561,000,0001,000,000,0004,150,000,000-2,941,000,000
CFO
5.12b
-27.86%
2,448,359,9203,499,664,9504,202,906,4304,283,000,0003,608,000,0005,375,000,0005,773,000,0005,060,000,0004,532,000,0005,171,000,0005,810,000,0006,890,000,0009,089,000,0008,134,000,0007,917,000,0008,207,000,0004,903,000,0005,089,000,0007,093,000,0005,117,000,000
Dividend
Apr 29, 20240.11 EUR/sh
Earnings
Mar 05, 2025

Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
URL
https://www.bayer.com/
IPO date
Nov 28, 1997
Employees
102,048
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
47,637,000
-6.11%
50,739,000
15.10%
44,081,000
6.48%
Cost of revenue
40,055,000
43,365,000
37,553,000
Unusual Expense (Income)
NOPBT
7,582,000
7,374,000
6,528,000
NOPBT Margin
15.92%
14.53%
14.81%
Operating Taxes
1,321,000
504,000
1,024,000
Tax Rate
17.42%
6.83%
15.69%
NOPAT
6,261,000
6,870,000
5,504,000
Net income
(2,941,000)
-170.87%
4,150,000
315.00%
1,000,000
-106.43%
Dividends
(2,379,000)
(1,965,000)
(1,963,000)
Dividend yield
7.19%
4.12%
4.25%
Proceeds from repurchase of equity
(1,000)
(10,000)
BB yield
0.00%
0.02%
Debt
Debt current
6,830,000
7,539,000
3,053,000
Long-term debt
39,414,000
35,015,000
37,643,000
Deferred revenue
467,000
602,000
810,000
Other long-term liabilities
14,291,000
15,757,000
19,451,000
Net debt
32,211,000
34,488,000
33,520,000
Cash flow
Cash from operating activities
5,117,000
7,093,000
5,089,000
CAPEX
(2,751,000)
(2,949,000)
(2,611,000)
Cash from investing activities
(4,014,000)
(2,381,000)
855,000
Cash from financing activities
(679,000)
(4,220,000)
(5,645,000)
FCF
15,017,000
(7,628,000)
4,526,000
Balance
Cash
10,587,000
10,153,000
7,739,000
Long term investments
3,446,000
(2,087,000)
(563,000)
Excess cash
11,651,150
5,529,050
4,971,950
Stockholders' equity
14,817,000
20,665,000
14,907,000
Invested Capital
81,190,850
89,489,950
86,771,050
ROIC
7.34%
7.80%
6.59%
ROCE
8.10%
7.70%
7.04%
EV
Common stock shares outstanding
982,420
982,420
982,420
Price
33.66
-30.64%
48.53
3.12%
47.06
-2.93%
Market cap
33,068,257
-30.64%
47,676,843
3.12%
46,232,685
-2.93%
EV
65,430,257
82,317,843
79,900,685
EBITDA
11,515,000
13,877,000
9,584,000
EV/EBITDA
5.68
5.93
8.34
Interest
2,047,000
1,857,000
1,347,000
Interest/NOPBT
27.00%
25.18%
20.63%